India may get COVID-19 vaccine by March 2021: Serum Institute of India | WeForNews | Latest News, Blogs India may get COVID-19 vaccine by March 2021: Serum Institute of India – WeForNews | Latest News, Blogs
Connect with us

Health

India may get COVID-19 vaccine by March 2021: Serum Institute of India

Currently, scientists, health researchers and drugmakers all over the world are racing to produce a safe and effective vaccine against coronavirus.

Published

on

COVID-19 Vaccine

New Delhi: The world at large pins hopes that vaccines will be the next big thing to prevent the increasing curve of COVID-19, the disease caused by the novel coronavirus or SARS-CoV-2. Currently, scientists, health researchers and drugmakers all over the world are racing to create one – but how long it will take to come to the fore is a curious question; by what time the entire population of India will get access to COVID-19 vaccine?, where do we stand in COVID-19 vaccine development? All these aspects were brought to discussion during Episode-9 of the HEAL-Thy Samvaad, organised by the ‘Healthcare Advocacy Group’ – HEAL Foundation in association with ICCIDD on 15th October 2020.

Experts are cautiously optimistic that we may, perhaps, get a vaccine by March next year, if everything goes as planned. Worldwide, about 40 vaccine candidates are in the race of vaccination. In India, 3 vaccines are in different stages of clinical trials. However, the COVID-19 crisis requires accelerated pathways for vaccine development. Proven success factors of H1N1 and Ebola have turned out as guiding principles in COVID-19 vaccine development. Union Health Minister Dr Harsh Vardhan has asserted that 400 million vaccines will be made available by next year.

“India may get COVID-19 vaccine by March 2021 provided the regulators signal with the processes fast as multiple manufacturers are working on it. India is heading fast towards vaccine development as two manufacturers are already in phase-3 trial and one in the phase-2 trial, while more players are joining the race. Usually, vaccine development takes 8-10 years, but this is the third time we are able to produce this one in a short time. The WHO has also taken initiative to make the process fast and easy, ” Dr Suresh Jadav, Executive Director, Serum Institute of India, Pvt Ltd., Pune, said while addressing India Vaccine Accessibility e-Summit at HEAL-Thy Samvaad and throwing light on – where do we stand in COVID-19 vaccine development.

“We can produce 700-800 million vaccine dosages every year once the things are streamlined. Although 55 per cent of the population is below 50 years of age, yet, as per the availability of vaccines, healthcare workers should get the vaccines first, then people over 60 years of age with comorbidities followed by the rest of the populace. As far as Serum Institute is concerned, we will be ready with 60-70 million dosages of vaccines by December 2020, but that will come in the market in 2021 after the clearance of licencing. Thereafter, we will produce more and more dosages by the permission of the government,” added Dr Jadav.

Speaking on the accessibility conundrum of COVID-19 vaccine in HEAL-Thy Samvaad, Dr J L Meena, Joint Director, NHA, said, “Of course, to have a check on the upsurge of COVID-19 infection, the vaccine is quintessential. However, the biggest challenge lies in its accessibility. The mechanism of the supply chain should also be redefined so that the distribution turns out equitably. For this, we need to prioritise the accessibility depending upon the vulnerability of the populace and take some strong action within the time limit. Effective governance is also required to carry out the judicious accessibility of the vaccine, which we have already.”

Recently, while attending an online WHO question-and-answer session, Dr Soumya Swaminathan, Chief Scientist, World Health Organization, reiterated that the WHO’s stance against allowing the virus to spread unchecked to reach herd immunity, emphasizing that the concept should be discussed only within the context of a vaccine.

Adding further, she said, “Once we have a vaccine, we can aim to have population immunity – herd immunity – because you’ll need to vaccinate at least 70 per cent of people, have them protected, to really break the transmission.”

Elaborating on the status of the vaccine development during HEAL-Thy Samvaad, Mr Samir Deb, pharmaceutical professional, consultant vaccine & public affairs consultant, South East Asia, said, “Vaccine development is a burning issue across the world now. Hopefully, 20-25 crore population will get a vaccine next year. Ensuring accessibility for 80 per cent of the population is a huge task indeed.”

Health

Researchers identify new drug to treat COVID-19 patients

In the continuing fight against the novel Coronavirus, researchers have now identified a drug with the potential to provide treatment for COVID-19 close to a year after it turned into a pandemic

Published

on

By

Coronavirus News

In the continuing fight against the novel Coronavirus, researchers have now identified a drug with the potential to provide treatment for COVID-19 close to a year after it turned into a pandemic.

The study, published in the journal Cells, found that the approved protease inhibitor aprotinin displayed activity against SARS-CoV-2, the coronavirus that causes COVID-19, in concentrations that are achieved in patients.

According to the researchers, aprotinin aerosols are approved in Russia for the treatment of influenza and could be readily tested for the treatment of COVID-19.

Aprotinin inhibits the entry of SARS-CoV-2 into host cells and may compensate for the loss of host cell protease inhibitors that are downregulated upon SARS-CoV-2 infection.

“The aprotinin aerosol has been reported to be tolerated extremely well in influenza patients. Hence, it may have a particular potential to prevent severe COVID-19 disease when applied early after diagnosis,” said study author Martin Michaelis from the University of Kent in the UK.

“Aprotinin has previously been shown to inhibit TMPRSS2 gene and has been suggested as a treatment option for influenza viruses and coronaviruses. Herein, we investigated the effects of aprotinin against SARS-CoV-2,” Michaelis added.

The findings showed that aprotinin displayed anti-SARS-CoV-2 activity in different cell types (Caco2, Calu-3, and primary bronchial epithelial cell air-liquid interface cultures) and against four virus isolates.

“An approved aprotinin aerosol may have the potential for the early local control of SARS-CoV-2 replication and the prevention of COVID-19 progression to a severe, systemic disease,” the study authors noted.

Continue Reading

Health

No dengue death in Delhi this year

Delhi govt announced zero death in the national capital due to dengue this year so far, giving credit to CM Kejriwal’s campaign against the mosquito-borne tropical disease caused by the dengue virus

Published

on

By

Arvind Kejriwal

Delhi government on Saturday announced zero death in the national capital due to dengue this year so far, giving credit to Chief Minister Arvind Kejriwal’s campaign against the mosquito-borne tropical disease caused by the dengue virus.

The announcement comes as it is going to organise the ninth week of ’10 Hafte 10 Baje, 10 Minute’ anti-dengue campaign on Sunday with Delhi Chief Minister Arvind Kejriwal appealing the citizen to join the movement.

“This is the second last week of the campaign and due to the aggressive campaign by the Delhi government this year no dengue-related death has been reported in the national capital,” the government said in a statement.

This week Delhi Health Minister Satyendar Jain also informed that no dengue-related death has been reported in the national capital this year and credited Kejriwal government’s anti-dengue campaign for this.

“Delhi people did it! No death due to dengue this year. There is also a sharp fall in number of cases compared to figures reported last year. Chief Minister Arvind Kejriwal’s campaign — ’10 hafte 10 baje 10 minute’ — has been made a success by you all,” Jain had tweeted.

As per the Delhi government statement, the Delhi model of fighting dengue is getting applauded across the country and Bollywood actor Amitabh Bachchan recently asked a question about the campaign to a contestant by playing a voice clip of the Delhi Chief Minister in the popular television show KBC.

Delhi Chief Minister Kejriwal earlier had urged citizens here for their collective efforts against the disease, saying “we have to stop the breeding of dengue mosquitoes and protect our family and the entire Delhi from Dengue.”

Kejriwal on last Sunday had also declared that dengue was “under control” in the national capital like previous year.

Last week, the anti-dengue campaign of the Delhi government got support from celebrities such as Shankar Mahadevan, who encouraged the citizens of Delhi to religiously follow the dengue prevention guidelines such as inspecting their residences for signs of stagnant water, draining the accumulated water or adding a layer of oil or petrol to it to prevent the breeding of mosquitoes.

The Delhi government this year launched a Dengue helpline — 01123300012 — and a WhatsApp helpline — 8595920530 — to assist the general public.

Continue Reading

Health

Sero Survey In Bhubaneswar: 50% Residents Develop Antibodies To Fight Coronavirus

Published

on

By

Coronavirus outbreak

Bhubaneswar: Half of the residents of Bhubaneswar have developed antibodies to fight novel Coronavirus. The statistics were revealed by ICMR – Regional Medical Research Centre (RMRC) Director, Dr Sanghamitra Pati today. Dr Pati said the survey was carried out between October 16 and 18 during which 1,400 samples were taken from all wards of Bhubaneswar Municipal Corporation (BMC).

As per the results, 50 per cent of Bhubaneswar’s population have been exposed to COVID-19, which means these many number of people now have the antibodies against the viral disease. “The results of the third sero survey corresponds to the status of infection, at least three weeks prior. So, there is much likelihood that exposure of people here to COVID-19 would have increased by now (October-end),” she said.

The good news is that 90 per cent of the people who are exposed to COVID-19 have very less or no symptoms. This implies that their immune system has been successful in fighting novel Coronavirus. Besides, 30 per cent of the people whose samples were collected have been tested through Rapid Antigen or RT-PCR, said Dr Pati.

Only around 2 per cent of Bhubaneswar’s population was found to be exposed to COVID-19 in the first sero survey. In the second survey in the last week of August, 5.1 per cent of the city’s population was exposed. Now, the result of the third sero survey is very encouraging, she said.

Continue Reading
Advertisement

Most Popular

Corona Virus (COVID-19) Live Data

COVID-19 affects different people in different ways. Most infected people will develop mild to moderate illness and recover without hospitalization.